Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
Despite consistent progress in prompt diagnosis and curative therapies in the last decade, lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties compared to prostate, breast, and other cancers. Statistics associate ~25% of 2021 cancer-related deaths with LC, more...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2023-01-01
|
| Series: | Exploration of Targeted Anti-tumor Therapy |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/etat/Article/1002171 |
| _version_ | 1797661936187342848 |
|---|---|
| author | Parth Malik Ruma Rani Raghu Solanki Vishal Haribhai Patel Tapan Kumar Mukherjee |
| author_facet | Parth Malik Ruma Rani Raghu Solanki Vishal Haribhai Patel Tapan Kumar Mukherjee |
| author_sort | Parth Malik |
| collection | DOAJ |
| description | Despite consistent progress in prompt diagnosis and curative therapies in the last decade, lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties compared to prostate, breast, and other cancers. Statistics associate ~25% of 2021 cancer-related deaths with LC, more than 80% of which are explicitly caused by tobacco smoking. Prevailing as small and non-small cell pathologies, with respective occurring frequency of nearly 15% and 80–85%, non-small cell LCs (NSCLCs) are prominently distinguished into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), subtypes. Since the first use of epidermal growth factor receptor (EGFR) inhibitor gefitinib for NSCLC treatment in 2002, immense progress has been made for targeted therapies with the next generation of drugs spanning across the chronological generations of small molecule inhibitors. The last two years have overseen the clinical approval of more than 10 therapeutic agents as first-line NSCLC medications. However, uncertain mutational aberrations as well as systemic resistant responses, and abysmal overall survival curtail the combating efficacies. Of late, immune checkpoint inhibitors (ICIs) against various molecules including programmed cell death-1 (PD-1) and its ligand (PD-L1) have been demonstrated as reliable LC treatment targets. Keeping these aspects in mind, this review article discusses the success of NSCLC chemo and immunotherapies with their characteristic effectiveness and future perspectives. |
| first_indexed | 2024-03-11T18:52:46Z |
| format | Article |
| id | doaj.art-8cbb1bab89884560bf6f43bdb57329ba |
| institution | Directory Open Access Journal |
| issn | 2692-3114 |
| language | English |
| last_indexed | 2024-03-11T18:52:46Z |
| publishDate | 2023-01-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Targeted Anti-tumor Therapy |
| spelling | doaj.art-8cbb1bab89884560bf6f43bdb57329ba2023-10-11T08:23:58ZengOpen Exploration Publishing Inc.Exploration of Targeted Anti-tumor Therapy2692-31142023-01-014585089510.37349/etat.2023.00171Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapiesParth Malik0https://orcid.org/0000-0003-1839-5701Ruma Rani1https://orcid.org/0000-0003-4858-0449Raghu Solanki2https://orcid.org/0000-0003-4970-9961Vishal Haribhai Patel3https://orcid.org/0000-0001-9217-3029Tapan Kumar Mukherjee4https://orcid.org/0000-0001-7247-5337Indian Council of Agricultural Research (ICAR)-National Research Centre on Equines, Hisar 125001, Haryana, IndiaSchool of Chemical Sciences, Central University of Gujarat, Gandhinagar 382030, Gujarat, IndiaSchool of Life Sciences, Central University of Gujarat, Gandhinagar 382030, Gujarat, IndiaDepartment of Biotechnology, Amity University, Kolkata 700156, West Bengal, IndiaInstitute of Biotechnology, Amity University, Kolkata 700156, West Bengal, IndiaDespite consistent progress in prompt diagnosis and curative therapies in the last decade, lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties compared to prostate, breast, and other cancers. Statistics associate ~25% of 2021 cancer-related deaths with LC, more than 80% of which are explicitly caused by tobacco smoking. Prevailing as small and non-small cell pathologies, with respective occurring frequency of nearly 15% and 80–85%, non-small cell LCs (NSCLCs) are prominently distinguished into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), subtypes. Since the first use of epidermal growth factor receptor (EGFR) inhibitor gefitinib for NSCLC treatment in 2002, immense progress has been made for targeted therapies with the next generation of drugs spanning across the chronological generations of small molecule inhibitors. The last two years have overseen the clinical approval of more than 10 therapeutic agents as first-line NSCLC medications. However, uncertain mutational aberrations as well as systemic resistant responses, and abysmal overall survival curtail the combating efficacies. Of late, immune checkpoint inhibitors (ICIs) against various molecules including programmed cell death-1 (PD-1) and its ligand (PD-L1) have been demonstrated as reliable LC treatment targets. Keeping these aspects in mind, this review article discusses the success of NSCLC chemo and immunotherapies with their characteristic effectiveness and future perspectives.https://www.explorationpub.com/Journals/etat/Article/1002171lung cancerimmunotherapychemotherapynon-small cell lung cancerimmune checkpoint inhibitorsadenocarcinomasquamous cell carcinoma |
| spellingShingle | Parth Malik Ruma Rani Raghu Solanki Vishal Haribhai Patel Tapan Kumar Mukherjee Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies Exploration of Targeted Anti-tumor Therapy lung cancer immunotherapy chemotherapy non-small cell lung cancer immune checkpoint inhibitors adenocarcinoma squamous cell carcinoma |
| title | Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies |
| title_full | Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies |
| title_fullStr | Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies |
| title_full_unstemmed | Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies |
| title_short | Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies |
| title_sort | understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non small cell lung cancers an update of resistant responses and recent combinatorial therapies |
| topic | lung cancer immunotherapy chemotherapy non-small cell lung cancer immune checkpoint inhibitors adenocarcinoma squamous cell carcinoma |
| url | https://www.explorationpub.com/Journals/etat/Article/1002171 |
| work_keys_str_mv | AT parthmalik understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies AT rumarani understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies AT raghusolanki understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies AT vishalharibhaipatel understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies AT tapankumarmukherjee understandingthefeasibilityofchemotherapeuticandimmunotherapeutictargetsagainstnonsmallcelllungcancersanupdateofresistantresponsesandrecentcombinatorialtherapies |